Wu L.Y., Kan C.N., Cheah I.K., Chong J.R., Xu X., Vrooman H., Hilal S., Venketasubramanian N., Chen C.P., Halliwell B., Lai M.K.P. Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics. Antioxidants. 2022;11(9):1717.
Rationale
Cross-sectional work by the same Singapore group showed lower plasma ET in MCI and dementia; this study asked the harder question — does low ET predict subsequent decline?
Methods
470 elderly memory-clinic attendees: baseline plasma ET, MRI for cerebrovascular burden and atrophy, full neuropsych battery; follow-up to 5 years with longitudinal models, dementia-subgroup and mediation analyses.
Results
- Low ET ↔ poorer baseline cognition and faster functional and multi-domain decline.
- Longitudinal associations significant only in non-demented participants — ET predicts decline at the pre-dementia stage, not established disease.
- Mediation: the ET–cognition link is largely explained by CeVD severity (white-matter hyperintensities) and atrophy — ET reads as a window onto vascular-structural brain health rather than a standalone neuroprotectant.
Conclusions
Plasma ET is a candidate prognostic biomarker for accelerated decline in pre-dementia — and the rationale for the pilot intervention trial (see ergothioneine-mci-pilot-2024).
Worth noting
The mediation result cuts both ways: it tempers "magic molecule" readings of ET while making ET genuinely useful as a clinical marker of early decline. Prospective design beats the cross-sections — but still observational; whether raising ET changes trajectory is what the pilot RCT is for.